Clinical Trial Contract Win

IXICO

17/11/2025 07:00

RNS Number : 6595H

IXICO plc

17 November 2025

 

IXICO plc

("IXICO", the "Company" or the "Group")

 

 Global Phase 3 clinical trial contract win worth over £3.5 million

 

 

17 November 2025 IXICO plc (AIM: IXI) - London, UK. IXICO, a global leader in neuroscience precision medicine and biomarker analytics, using its AI-driven platform to help advance drug development in neurological disorders, today announced that it has signed a new commercial contract with a global pharmaceutical company to provide imaging services for a worldwide Phase 3 clinical trial in Huntington's Disease (HD). The total contract value is over £3.5m over four years.

 

Significant progress is being made in HD treatment research fuelling hope for patients. The disease is a rare, hereditary neurodegenerative disorder that leads to the progressive breakdown of nerve cells in the brain, affecting motor skills, cognitive function, mood, and emotional well-being.  IXICO has deep expertise and experience in HD with the Company being recognised as a key participant in the HD ecosystem due to its advanced HD biomarker innovation, precise clinical trial management and state-of-the-art image analysis.  

 

The positive commercial momentum continues IXICO's successful execution of its 'Innovate, Lead, Scale' strategy to drive global expansion and growth.

 

Bram Goorden, CEO of IXICO, commented: "This is an important contract in terms of value and trial stage that further cements IXICO's position in the field.  We are very proud to continue our support of the HD community, working with HD research consortia and pharmaceutical partners towards breakthrough treatments for patients in this devastating disease. As mentioned during the recent Capital Markets Day, I am greatly encouraged by biopharma's increased commitment to invest in rare neurological diseases and optimistic this will lead to disease modifying solutions in the near future."

 

The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulation (EU) No. 596/2014 as amended by The Market Abuse (Amendment) (EU Exit) Regulations 2019. Upon the publication of this announcement via the Regulatory Information Service, this inside information is now considered to be in the public domain.

Ends

 

For further information please contact:

IXICO plc
+44 (0) 20 3763 7499
Grant Nash, Chief Financial Officer
James Chandler, Chief Business Officer
Cavendish Capital Markets Limited
(Nominated Adviser and Sole Broker)
+44 (0) 20 7220 0500
Giles Balleny (Corporate Finance)
Nigel Birks (Healthcare Specialist Sales)
Harriet Ward (Corporate Broking)
Michael F Johnson (Sales)


 

About IXICO www.IXICO.com

IXICO is a global leader in neuroscience imaging and biomarker analytics, using its proprietary AI-driven platform to help advance the treatment of neurological disorders and reduce the uncertainties associated with drug discovery, development and monitoring.   As a key part of the global neurological disease research community, the Company has built a global reputation and 20-year track record as an end-to-end Imaging Contract Research Organisation (iCRO) working with leading pharma companies, innovative biotech's, disease consortia and non-profit organisations. IXICO has supported hundreds of neurological clinical trials, analysed hundreds of thousands scans and built an expansive network of expert imaging centres around the world.  

 

The IXICO Platform is tailor-made for neurological disease, reliably processing data from global trials, precisely measuring key imaging biomarkers associated with the identification, progression and treatment of diseases such as Alzheimer's, Huntington's and Parkinson's.  Image data is interrogated by the Platform and IXICO's expert scientists translating complex data into clinically meaningful while minimizing data variability and increasing reproducibility.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 
  END

 

 
CNTGZMMMKDZGKZM